69
Views
7
CrossRef citations to date
0
Altmetric
Review

Multi-drug resistance and cancer

Pages 511-520 | Published online: 02 May 2007
 

Abstract

Development of drug resistance during chemotherapy is the leading cause of treatment failure and decreased survival in cancer patients. Drug resistance can occur in many ways, such as altering the targets or the metabolism of the drug, and multi-drug resistance is one of the most extensively studied forms for > 30 years. The members of the ATP-binding cassette protein family are responsible for multi-drug resistance. There has been a tremendous amount of work done to overcome multi-drug resistance, but real success has not been achieved to date. Pharmacological modulation of the transporters seems to be the first choice, but the effectivity observed in preclinical studies did not translate into a success in clinical applications with the agents developed for this purpose. New strategies to increase the drug efficacy will be the manipulating of multi-drug resistance genes at transcriptional or translational level or targeting mutant genes and replacing or destroying them, rendering the drug resistance proteins ineffective. The research should be directed to the individualised therapies to overcome drug resistance in the future.

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 99.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 1,757.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.